Literature DB >> 22871158

Synthesis, aqueous reactivity, and biological evaluation of carboxylic acid ester-functionalized platinum-acridine hybrid anticancer agents.

Leigh A Graham1, Jimmy Suryadi, Tiffany K West, Gregory L Kucera, Ulrich Bierbach.   

Abstract

The synthesis of platinum-acridine hybrid agents containing carboxylic acid ester groups is described. The most active derivatives and the unmodified parent compounds showed up to 6-fold higher activity in ovarian cancer (OVCAR-3) and breast cancer (MCF-7, MDA-MB-231) cell lines than cisplatin. Inhibition of cell proliferation at nanomolar concentrations was observed in pancreatic (PANC-1) and nonsmall cell lung cancer cells (NSCLC, NCI-H460) of 80- and 150-fold, respectively. Introduction of the ester groups did not affect the cytotoxic properties of the hybrids, which form the same monofunctional-intercalative DNA adducts as the parent compounds, as demonstrated in a plasmid unwinding assay. In-line high-performance liquid chromatography and electrospray mass spectrometry (LC-ESMS) shows that the ester moieties undergo platinum-mediated hydrolysis in a chloride concentration-dependent manner to form carboxylate chelates. Potential applications of the chloride-sensitive ester hydrolysis as a self-immolative release mechanism for tumor-selective delivery of platinum-acridines are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871158      PMCID: PMC3478695          DOI: 10.1021/jm300879k

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  32 in total

Review 1.  Development of self-immolative dendrimers for drug delivery and sensing.

Authors:  Rongsheng E Wang; Frankie Costanza; Youhong Niu; Haifan Wu; Yaogang Hu; Whitney Hang; Yiqun Sun; Jianfeng Cai
Journal:  J Control Release       Date:  2011-12-01       Impact factor: 9.776

2.  Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells.

Authors:  Xin Qiao; Alexandra E Zeitany; Marcus W Wright; Amal S Essader; Keith E Levine; Gregory L Kucera; Ulrich Bierbach
Journal:  Metallomics       Date:  2012-03-29       Impact factor: 4.526

3.  Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.

Authors:  Hana Kostrhunova; Jaroslav Malina; Amanda J Pickard; Jana Stepankova; Marie Vojtiskova; Jana Kasparkova; Tereza Muchova; Matthew L Rohlfing; Ulrich Bierbach; Viktor Brabec
Journal:  Mol Pharm       Date:  2011-08-17       Impact factor: 4.939

4.  Design, synthesis, and biological activity of a novel non-cisplatin-type platinum-acridine pharmacophore.

Authors:  E T Martins; H Baruah; J Kramarczyk; G Saluta; C S Day; G L Kucera; U Bierbach
Journal:  J Med Chem       Date:  2001-12-06       Impact factor: 7.446

Review 5.  The role of sulfur in platinum anticancer chemotherapy.

Authors:  Xiaoyong Wang And; Zijian Guo
Journal:  Anticancer Agents Med Chem       Date:  2007-01       Impact factor: 2.505

6.  Bis(acridinylthiourea)platinum(II) complexes: synthesis, DNA affinity, and biological activity in glioblastoma cells.

Authors:  Todd M Augustus; Joel Anderson; Suzanne M Hess; Ulrich Bierbach
Journal:  Bioorg Med Chem Lett       Date:  2003-03-10       Impact factor: 2.823

7.  Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates.

Authors:  Hemanta Baruah; Christopher L Rector; Susanne M Monnier; Ulrich Bierbach
Journal:  Biochem Pharmacol       Date:  2002-07-15       Impact factor: 5.858

8.  Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.

Authors:  Meredith A Morgan; Leslie A Parsels; Joshua D Parsels; Alefiyah K Mesiwala; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

Review 9.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

10.  Characterization of the bisintercalative DNA binding mode of a bifunctional platinum-acridine agent.

Authors:  Jayati Roy Choudhury; Ulrich Bierbach
Journal:  Nucleic Acids Res       Date:  2005-09-28       Impact factor: 16.971

View more
  6 in total

1.  Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent.

Authors:  Cale D Fahrenholtz; Song Ding; Brian W Bernish; Mariah L Wright; Ye Zheng; Mu Yang; Xiyuan Yao; George L Donati; Michael D Gross; Ulrich Bierbach; Ravi Singh
Journal:  J Inorg Biochem       Date:  2016-07-27       Impact factor: 4.155

2.  Cellular Recognition and Repair of Monofunctional-Intercalative Platinum--DNA Adducts.

Authors:  Fang Liu; Jimmy Suryadi; Ulrich Bierbach
Journal:  Chem Res Toxicol       Date:  2015-10-16       Impact factor: 3.739

3.  Redesigning the DNA-targeted chromophore in platinum-acridine anticancer agents: a structure-activity relationship study.

Authors:  Amanda J Pickard; Fang Liu; Thomas F Bartenstein; Laura G Haines; Keith E Levine; Gregory L Kucera; Ulrich Bierbach
Journal:  Chemistry       Date:  2014-10-10       Impact factor: 5.236

4.  Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.

Authors:  Song Ding; Amanda J Pickard; Gregory L Kucera; Ulrich Bierbach
Journal:  Chemistry       Date:  2014-10-10       Impact factor: 5.236

5.  GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates.

Authors:  Ran Liu; Zheng Fu; Meng Zhao; Xiangqian Gao; Hong Li; Qian Mi; Pengxing Liu; Jinna Yang; Zhi Yao; Qingzhi Gao
Journal:  Oncotarget       Date:  2017-06-13

6.  Evaluation of a Platinum-Acridine Anticancer Agent and Its Liposomal Formulation in an in vivo Model of Lung Adenocarcinoma.

Authors:  Song Ding; Christopher L Hackett; Fang Liu; Ryan G Hackett; Ulrich Bierbach
Journal:  ChemMedChem       Date:  2020-10-22       Impact factor: 3.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.